Neglected Disease(s)   Technologies Available for Licensing from NIH/FDA No NIH/FDA Technology Abstracts are available for this Neglected Disease/Condition at this time. Technologies Available for Licensing from Non-Profit Institutions African Trypanosomiasis The Johns Hopkins University New Uses For Camptothecin Analogs Ref# C09727 Chagas disease Tufts University Neuroprotective Role Of A Novel Neurotrophic Factor (pdnf) Tufts University Neurotrophic Activities Of Pdnf-derived Y21 Peptide Leishmaniasis Harvard University New Delivery Device For Protein Therapeutics And Vaccines The Johns Hopkins University New Uses For Camptothecin Analogs Ref# C09727 Malaria Harvard University Next Generation Pulmonary Malarial Vaccine Boston University Novel Transcription Factor Regulating Tnf-alpha Dana-Farber Cancer Institute Inhibitors Of P. Carinii: Dihydrofolate Reductase With Marked Improved In Potency Relative To Trimethoprim And Species Selectivity Relative To Piritrexim Harvard University New Delivery Device For Protein Therapeutics And Vaccines Yeda R&D Co. Ltd. - Technology Transfer from the W New Antimalarial Compounds Tufts University Link Between Immune Response And Parasite Synchronization In Malaria Overview African Trypanosomiasis Chagas disease Leishmaniasis Malaria

Note that this site uses cookies, Click here for more information.